Literature DB >> 14521805

Current research directions for locally advanced cervix cancer.

Harry J Long1.   

Abstract

Chemoradiotherapy with either weekly doses of cisplatin or the combination of 5-fluorouracil and cisplatin has become the standard of therapy for patients with locally advanced cervix cancer. Recently reported studies that are directed at improvements in radiation treatment planning, improved tissue oxygenation, and neoadjuvant chemotherapy are likely to lead to improvements in therapy. Nonsurgical preoperative staging with positron emission tomography and sentinel lymph node evaluation could result in effective surgical staging, or even nonsurgical staging, more accurate radiation treatment planning, and improved local and systemic control with a reduction in short-term and long-term morbidity in the treatment of locally advanced cervix cancer. Well-designed, randomized, prospective clinical trials are needed for a more thorough evaluation of these preliminary findings and to set research directions for the next several years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521805     DOI: 10.1007/s11912-003-0007-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  24 in total

1.  Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects.

Authors:  C Fellner; R Pötter; T H Knocke; A Wambersie
Journal:  Radiother Oncol       Date:  2001-01       Impact factor: 6.280

Review 2.  Is concurrent chemotherapy and radiotherapy the new standard of care for locally advanced cervical cancer?

Authors:  M Lehman; G Thomas
Journal:  Int J Gynecol Cancer       Date:  2001 Mar-Apr       Impact factor: 3.437

3.  Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer.

Authors:  A Fyles; M Milosevic; D Hedley; M Pintilie; W Levin; L Manchul; R P Hill
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

4.  Tumor vascularity: a histological measure of angiogenesis and hypoxia.

Authors:  C M West; R A Cooper; J A Loncaster; D P Wilks; M Bromley
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Set-up verification of cervix cancer patients treated with long treatment fields; implications of a non-rigid bony anatomy.

Authors:  S Quint; H C de Boer; J R van Sörnsen de Koste; B J Heijmen; M J Olofsen-van Acht
Journal:  Radiother Oncol       Date:  2001-07       Impact factor: 6.280

6.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

Authors:  C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

7.  Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements.

Authors:  M Milosevic; A Fyles; D Hedley; M Pintilie; W Levin; L Manchul; R Hill
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

8.  Image-based dose planning of intracavitary brachytherapy: registration of serial-imaging studies using deformable anatomic templates.

Authors:  G E Christensen; B Carlson; K S Chao; P Yin; P W Grigsby; K Nguyen; J F Dempsey; F A Lerma; K T Bae; M W Vannier; J F Williamson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

9.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

10.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

Authors:  H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

View more
  2 in total

1.  Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico.

Authors:  M A Terán-Porcayo; I Zeichner-Gancz; R A C Gomez del-Castillo; A Beltrán-Ortega; G Solorza-Luna
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Angiogenesis in cancer.

Authors:  Naoyo Nishida; Hirohisa Yano; Takashi Nishida; Toshiharu Kamura; Masamichi Kojiro
Journal:  Vasc Health Risk Manag       Date:  2006
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.